|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus(2019-nCoV) infected pneumonia(standard version)显示文摘In December 2019, a new type viral pneumonia cases occurred in Wuhan, Hubei Province;and then named '2019 novel coronavirus(2019-nCoV)' by the World Health Organization(WHO) on 12 January 2020. For it is a never been experienced respiratory disease before and with infection ability widely and quickly, it attracted the world’s attention but without treatment and control manual. For the request from frontline clinicians and public health professionals of 2019-nCoV infected pneumonia management, an evidence-based guideline urgently needs to be developed. Therefore, we drafted this guideline according to the rapid advice guidelines methodology and general rules of WHO guideline development;we also added the first-hand management data of Zhongnan Hospital of Wuhan University. This guideline includes the guideline methodology, epidemiological characteristics, disease screening and population prevention, diagnosis, treatment and control(including traditional Chinese Medicine), nosocomial infection prevention and control, and disease nursing of the 2019-nCoV. Moreover, we also provide a whole process of a successful treatment case of the severe 2019-nCoV infected pneumonia and experience and lessons of hospital rescue for 2019-nCoV infections. This rapid advice guideline is suitable for the first frontline doctors and nurses, managers of hospitals and healthcare sections, community residents, public health persons, relevant researchers, and all person who are interested in the 2019-nCoV. | Ying-Hui Jin Lin Cai Zhen-Shun Cheng Hong Cheng Tong Deng Yi-Pin Fan Cheng Fang Di Huang Lu-Qi Huang Qiao Huang Yong Han Bo Hu Fen Hu Bing-Hui Li Yi-Rong Li Ke Liang Li-Kai Lin Li-Sha Luo Jing Ma Lin-Lu Ma Zhi-Yong Peng Yun-Bao Pan Zhen-Yu Pan Xue-Qun Ren Hui-Min Sun Ying Wang Yun-Yun Wang Hong Weng Chao-Jie Wei Dong-Fang Wu Jian Xia Yong Xiong Hai-Bo Xu Xiao-Mei Yao Yu-Feng Yuan Tai-Sheng Ye Xiao-Chun Zhang Ying-Wen Zhang Yin-Gao Zhang Hua-Min Zhang Yan Zhao Ming-Juan Zhao Hao Zi Xian-Tao Zeng Yong-Yan Wang Xing-Huan Wang 无 | 2020 | Military Medical Research2020，7，1： | 161 |
| 2 | Analysis of status and countermeasures of cancer incidence and mortality in China显示文摘Cancer is the leading cause of human deaths in the world and produces serious economic burdens. On September 12, 2018, the academic journal A Cancer Journal for Clinicians published an article about the latest statistics of cancers worldwide, which provided a status report on the global burden of 36 cancers in 185 countries worldwide. Cancer has also become a serious public health problem in China and caused more and more attention of the government and people in recent years. This review analyzes the incidence, mortality and prevalent trend of cancers in China, discusses the reasons behind this status, and reviews the potential countermeasures for cancer prevention and control in China. | Chunchun Wu Mengna Li Hanbing Meng Yukun Liu Weihong Niu Yao Zhou Ran Zhao Yumei Duan Zhaoyang Zeng Xiaoling Li Guiyuan Li Wei Xiong Ming Zhou | 2019 | Science China(Life Sciences)2019，62，5： | 175 |
| 3 | Intracellular tat of human immunodeficiency virus type 1 activates lytic cycle replication of Kaposi's sarcoma-associated herpesvirus. Role of JAK/STAT signaling显示文摘 | Zeng, Y. Zhang, X. H. Huang, Z. Cheng, L. Yao, S. H. Qin, D. Chen, X. Y. Tang, Q. Lv, Z. G. Zhang, L. Lu, C. | 2007 | 南京医科大学学报(自然科学版)2007，27，5： | 31 |
| 4 | Clinical Research on Alzheimer's Disease: Progress and Perspectives显示文摘Alzheimer's disease(AD), the most common type of dementia, is becoming a major challenge for global health and social care. However, the current understanding of AD pathogenesis is limited, and no early diagnosis and disease-modifying therapy are currently available. During the past year, significant progress has been made in clinical research on the diagnosis, prevention, and treatment of AD.In this review, we summarize the latest achievements,including diagnostic biomarkers, polygenic hazard score,amyloid and tau PET imaging, clinical trials targeting amyloid-beta(Ab), tau, and neurotransmitters, early intervention, and primary prevention and systemic intervention approaches, and provide novel perspectives for further efforts to understand and cure the disease. | Bin-Lu Sun Wei-Wei Li Chi Zhu Wang-Sheng Jin Fan Zeng Yu-Hui Liu Xian-Le Bu Jie Zhu Xiu-Qing Yao Yan-Jiang Wang | 2018 | Neuroscience Bulletin2018，34，6： | 29 |
| 5 | Clinical effects and complications of TIPS for portal hypertension due to cirrhosis:A single center显示文摘AIM:To determine the clinical effects and complications of transjugular intrahepatic portosystemic shunt(TIPS)for portal hypertension due to cirrhosis.METHODS:Two hundred and eighty patients with portal hypertension due to cirrhosis who underwent TIPS were retrospectively evaluated.Portal trunk pressure was measured before and after surgery.The changes in hemodynamics and the condition of the stent were assessed by ultrasound and the esophageal and fundic veins observed endoscopically.RESULTS:The success rate of TIPS was 99.3%.The portal trunk pressure was 26.8±3.6 cmH2O after surgery and 46.5±3.4 cmH2O before surgery(P<0.01).The velocity of blood flow in the portal vein increased.The internal diameters of the portal and splenic veins were reduced.The short-term hemostasis rate was100%.Esophageal varices disappeared completely in68%of patients and were obviously reduced in 32%.Varices of the stomach fundus disappeared completely in 80%and were obviously reduced in 20%of patients.Ascites disappeared in 62%,were markedly reduced in 24%,but were still apparent in 14%of patients.The total effective rate of ascites reduction was 86%.Hydrothorax completely disappeared in 100%of patients.The incidence of post-operative stent stenosis was 24%at 12 mo and 34%at 24 mo.The incidence of post-operative hepatic encephalopathy was 12%at3 mo,17%at 6 mo and 19%at 12 mo.The incidence of post-operative recurrent hemorrhage was 9%at 12mo,19%at 24 mo and 35%at 36 mo.The cumulative survival rate was 86%at 12 mo,81%at 24 mo,75%at 36 mo,57%at 48 mo and 45%at 60 mo.CONCLUSION:TIPS can effectively lower portal hypertension due to cirrhosis.It is significantly effective for hemorrhage of the digestive tract due to rupture of esophageal and fundic veins and for ascites and hydrothorax caused by portal hypertension. | Jian-Ping Qin Ming-De Jiang Wen Tang Xiao-Ling Wu Xin Yao Wei-Zheng Zeng Hui Xu Qian-Wen He Ming Gu | 2013 | World Journal of Gastroenterology2013，19，44： | 25 |
| 6 | Efficacy of intramuscular matrine in the treatment of chronic hepatitis B显示文摘BACKGROUND: Hepatitis B virus (HBV) infection, a glo- bal public health problem, is the leading cause of cirrhosis and hepatocellular carcinoma (HCC) worldwide. There are more than 350 million HBV carriers in the world and up to one million die annually due to hepatitis B associated liv- er disease. So far no optimal treatment is available for pa- tients with chronic hepatitis B. In the paper we investigated the efficacy of intramuscular matrine in the treatment of chronic hepatitis B. METHODS: One hundred and twenty patients with chronic hepatitis B were randomly divided into matrine treatment group (n =60) and control group (n =60). The patients of the matrine group were given intramuscularly with matrine (an alkaloid extracted from a traditional Chinese herb Radix Sophorae Flavescentis by Guangzhou Ming Xing Pharmaceu cal Factory, Guangzhou, China) of 100 mg daily for 90 days in addition to conventional liver-protective drugs in- cluding glucurone, inosine, compound vitamin B and caryophyllin. The control group received conventional liv- er-protective drugs alone. Clinical manifestations and labo- ratory parameters including liver biochemistry and serum hepatitis B virus markers were monitored before and after treatment in the two groups. RESULTS: Significant differences were seen between the two groups in terms of improvement of clinical symptoms and signs, recovery of liver functions, and serum conver- sion from hepatitis Be antigen to HBe antibody and from positive to negative serum HBV DNA (P <0.05-0.01). The result of the matrine group was more marked than that of the control group. Serious side-effects were not observed except mild pain at the site of injection of matrine in a few patients. CONCLUSION: These results indicate that intramuscular matrine may be an economical, efficacious, safe drug for the treatment of chronic hepatitis B. | Yao Long, Xiao-Tian Lin, Kun-Lun Zeng and Lian Zhang Zhanjiang, China Department of Infectious Diseases, Affiliated Hospital of Guangdong Medical College, Zhanjiang 524001, China Haibin Centre Hospital, Zhanjiang 524005, China Centre of Hepatology of Nanfang Hospital, First Military Medical University, Guang- zhou 510515, China | 2004 | Hepatobiliary & Pancreatic Diseases International2004，3，1： | 21 |
| 7 | Clinical trial with traditional Chinese medicine intervention ''tonifying the kidney to promote liver regeneration and repair by affecting stem cells and their microenvironment'' for chronic hepatitis B-associated liver failure显示文摘AIM:To study the clinical efficacy of traditional Chinese medicine(TCM)intervention'tonifying the kidney to promote liver regeneration and repair by affecting stem cells and their microenvironment'('TTK')for treating liver failure due to chronic hepatitis B.METHODS:We designed the study as a randomized controlled clinical trial.Registration number of Chinese Clinical Trial Registry is Chi CTR-TRC-12002961.A total of 144 patients with liver failure due to infection with chronic hepatitis B virus were enrolled in this randomized controlled clinical study.Participants were randomly assigned to the following three groups:(1)a modern medicine control group(MMC group,36patients);(2)a'tonifying qi and detoxification'('TQD')group(72 patients);and(3)a'tonifying the kidney to promote liver regeneration and repair by affecting stem cells and their microenvironment'('TTK')group(36patients).Patients in the MMC group received general internal medicine treatment;patients in the'TQD'group were given a TCM formula'tonifying qi and detoxification'and general internal medicine treatment;patients in the'TTK'group were given a TCM formula of'TTK'and general internal medicine treatment.All participants were treated for 8 wk and then followed at 48 wk following their final treatment.The primaryefficacy end point was the patient fatality rate in each group.Measurements of various virological and biochemical indicators served as secondary endpoints.The one-way analysis of variance and the t-test were used to compare patient outcomes in the different treatment groups.RESULTS:At the 48-wk post-treatment time point,the patient fatality rates in the MMC,'TQD',and'TTK'groups were 51.61%,35.38%,and 16.67%,respectively,and the differences between groups were statistically significant(P<0.05).However,there were no significant differences in the levels of hepatitis B virus DNA or prothrombin activity among the three groups(P>0.05).Patients in the'TTK'group had significantly higher levels of serum total bilirubin compared to MMC subjects(339.40μmol/L±270.09μmol/L vs 176.13μmol/L±185.70μmol/L,P=0.014).Serum albumin levels were significantly increased in both the'TQD'group and'TTK'group as compared with the MMC group(31.30 g/L±4.77g/L,30.72 g/L±2.89 g/L vs 28.57 g/L±4.56 g/L,P<0.05).There were no significant differences in levels of alanine transaminase among the three groups(P>0.05).Safety data showed that there was one case of stomachache in the'TQD'group and one case of gastrointestinal side effect in the'TTK'group.CONCLUSION:Treatment with'TTK'improved the survival rates of patients with liver failure due to chronic hepatitis B.Additionally,liver tissue was regenerated and liver function was restored. | Han-Min Li Zhi-Hua Ye Jun Zhang Xiang Gao Yan-Ming Chen Xin Yao Jian-Xun Gu Lei Zhan Yang Ji Jian-Liang Xu Ying-He Zeng Fan Yang Lin Xiao Guo-Guang Sheng Wei Xin Qi Long Qing-Jing Zhu Zhao-Hong Shi Lian-Guo Ruan Jia-Yao Yang Chang-Chun Li Hong-Bin Wu Sheng-Duo Chen Xin-La Luo | 2014 | World Journal of Gastroenterology2014，20，48： | 20 |
| 8 | Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer显示文摘渗入肿瘤的 Tregs 的起源,肿瘤免疫力的抑制的批评调停人,是不清楚的。这里,,我们证明在人的乳癌的渗入肿瘤的天真的 CD4 + T 房间和 Tregs 有重叠 TCR 全部剧目几乎别与传播 Tregs 重叠,建议 intratumoral Tregs 主要在 situ 而非从招募的 Tregs 从天真的 T 房间发展。而且,许多天真的 CD4 + T 房间和 Tregs 密切被相关,两个显示的穷人为乳癌病人的预后。天真的 CD4 + T 房间与许多生产 CCL18 巨噬细胞成比例遵守肿瘤片。而且,采纳地转移的人的天真的 CD4 + T 房间以一种 CCL18 依赖的方式渗入人的乳癌 orthotopic 异种皮移植。在在人性化的鼠标的人的乳癌异种皮移植,由将 PITPNM3 的表达式击倒堵住天真的 CD4 + T 房间的招募进肿瘤, CCL18 受体,显著地减少 intratumoral Tregs 并且禁止肿瘤前进。这些调查结果建议那个乳房渗入肿瘤的 Tregs 从在 situ 区分进 Tregs 的传播天真的 CD4 + T 房间的趋化性产生。由防碍 CCL18 的 PITPNM3 识别禁止天真的 CD4 + T 房间招募进肿瘤可以是为 anticancer 免疫疗法的吸引人的策略。 | Shicheng Su Jianyou Liao Jiang Liu Di Huang Chonghua He Fei Chen LinBing Yang Wei Wu Jianing Chen Ling Lin Yunjie Zeng Nengtai Ouyang Xiuying Cui Herui Yao Fengxi Su Jian-dong Huang Judy Lieberman Qiang Liu Erwei Song | 2017 | Cell Research2017，27，4： | 19 |
| 9 | Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy(STRATEGY):a multicenter,randomized,controlled,non-inferiority clinical trial显示文摘Despite the current guideline's recommendation of a timely stepwise intensification therapy,the 'clinical inertia',termed as the delayed treatment intensification,commonly exists in the real world,which may be partly due to the relatively little substantial evidence and no clear consensus regarding the efficacy and safety of triple oral agents in patients inadequately controlled with dual therapy.In this clinical trial performed in 237 centers in China,5,535 type 2 diabetic patients inadequately controlled by previous therapies were treated with a stable metformin/sitagliptin dual therapy for 20 weeks.The patients who did not reach the glycated hemoglobin A1c(HbA1c) goal were then further randomized into glimepiride,gliclazide,repaglinide,or acarbose group for an additional 24-week triple therapy.A mean HbAlc reduction of 0.85%was observed when sitagliptin was added to the patients inadequately controlled with metformin in 16 weeks.Further HbAlc reductions in the 24-week triple therapy stage were 0.65%in glimepiride group,0.70%in gliclazide group,0.61%in repaglinide group,and 0.45%in acarbose group.The non-inferiority criterion for primary hypotheses was met for gliclazide and repaglinide,but not for acarbose,compared with glimepiride,when added to metformin/sitagliptin dual therapy.The incidences of adverse events(AEs) were 29.2%in the dual therapy stage and30.3%in the triple therapy stage.Metformin/sitagliptin as baseline therapy,with the addition of a third oral antihyperglycemic agent,including glimepiride,gliclazide,repaglinide,or acarbose,was effective,safe and well-tolerated for achieving an HbAlc<7.0%goal in type 2 diabetic patients inadequately controlled with previous therapies.The timely augmentation of up to three oral antihyperglycemic agents is valid and of important clinical benefit to prevent patients from exposure to unnecessarily prolonged hyperglycemia. | Wen Xu Yiming Mu Jiajun Zhao Dalong Zhu Qiuhe Ji Zhiguang Zhou Bin Yao Anhua Mao Samuel S.Engel Bin Zhao Yan Bi Longyi Zeng Xingwu Ran Juming Lu Linong Ji Wenying Yang Weiping Jia Jianping Weng | 2017 | Science China(Life Sciences)2017，60，3： | 19 |
| 10 | contrast enhanced computed tomography and reconstruction of hepatic vascular system for transjugular intrahepatic portal systemic shunt puncture path planning显示文摘AIM: To describe a method for the transjugular intrahepatic portal systemic shunt(TIPS) placement performed with the aid of contrast-enhanced computed tomography(CECT) and three-dimensional reconstructed vascular images(3D RVIs), and to assess its safety and effectiveness. METHODS: Four hundred and ninety patients were treated with TIPS between January 2005 and December 2012. All patients underwent liver CECT and reconstruction of 3D RVIs of the right hepatic vein to portal vein(PV) prior to the operation. The 3D RVIs were carefully reviewed to plan the puncture path fromthe start to target points for needle pass through the PV in the TIPS procedure. R E S U LTS :The improved TIPS procedure was successful in 483(98.6%) of the 490 patients. The number of punctures attempted was one in 294(60%) patients, 2 to 3 in 147(30%) patients, 4 to 6 in 25(5.1%) patients and more than 6 in 17(3.5%) patients. Seven patients failed. Of the 490 patients, 12 had punctures into the artery, 15 into the bile duct, eight into the gallbladder, and 18 through the liver capsule. Analysis of the portograms from the 483 successful cases indicated that the puncture points were all located distally to the PV bifurcation on anteroposterior images, while the points were located proximally to the bifurcation in the three cases with intraabdominal bleeding. The complications included three cases of bleeding, of whom one died and two needed surgery. CONCLUSION: Use of CECT and 3D RVIs to plan the puncture path for TIPS procedure is safe, simple and effective for clinical use. | Jian-Ping Qin Shan-Hong Tang Ming-De Jiang Qian-Wen He Hong-Bin Chen Xin Yao Wei-Zheng Zeng Ming Gu | 2015 | World Journal of Gastroenterology2015，21，32： | 17 |
| 11 | 功能的限制的积极选择而非松驰在鸡驯服期间驾驶视觉的进化显示文摘是由达尔文,注意了鸡有所有鸟,而是国内鸡和他们的野祖先之间的有趣的进化差别的最大的 phenotypic 差异,红 Junglefowl,是他们的比较地更弱的视觉。存在理论建议在国内鸡之中的减少的视觉英勇反映功能的限制的松驰在识别负责的内在的基因机制的视觉,而是证据上驾驶的变化因为这个变化决定性地没被描绘。这里,国内鸡的染色体宽的分析和红 Junglefowl 染色体为涉及视觉的发展的断然选择的基因显示出重要丰富。关于为在视网膜的这些基因的 mRNA 表示的水平国内鸡和他们的野祖先之间有重要差别。涉及视觉的发展的众多的另外的基因也在在国内鸡和他们的野祖先之间的 mRNA 表示显示出重要差别,特别地为与 phototransduction 和光敏电阻器开发联系的基因,例如 RHO (视紫红质) , GUCA1A, PDE6B 和 NR2E3。最后,我们在视觉描绘了 VIT 基因的潜在的角色,它在村庄鸡的视网膜经历了积极选择和 downregulated 表示。总的来说,我们的结果建议净化选择的那种积极选择,而非松驰,在国内鸡贡献了视觉的进化。怀有更弱的视觉的国内鸡的祖先可能显示出减少的害怕回答和警戒,使他们更安逸无意识地被选择或驯养。 | Ming-Shan Wang Rong-wei Zhang Ling-Yan Su Yah Li Min-Sheng Peng He-Qun Liu Lin Zeng David M Irwin Jiu-Lin Du Yong-Gang Yao Dong-Dong Wu Ya-Ping Zhang | 2016 | Cell Research2016，26，5： | 15 |
| 12 | Early Serum HBsAg Kinetics as Predictor of HBsAg Loss in Patients with HBeAg-Negative Chronic Hepatitis B after Treatment with Pegylated Interferonα-2a显示文摘Hepatitis B surface antigen(HBsAg)loss is an ideal treatment endpoint for patients with chronic hepatitis B(CHB).We investigated the predictive value of on-treatment HBsAg levels for HBsAg loss in hepatitis B e antigen(HBe Ag)-negative CHB patients who received 120-week PEG-IFNα-2a treatment.Serum HBV DNA,HBsAg,and anti-HBs levels were assayed at baseline and every 3 months during the treatment.Of 81 patients,12 achieved HBsAg loss,20 achieved HBsAg\100 IU/mL,and 49 maintained HBs Ag C 100 IU/mL.HBsAg loss rate was only 3.7%at 48 weeks,while it reached to 11.1%and 14.8%after treatment of 96 weeks and 120 weeks.The cutoff HBs Ag levels at 12 weeks predicting HBsAg loss at 96 weeks and 120 weeks of treatment were 400 IU/mL and 750 IU/mL,with AUC 0.725 and 0.722,positive predictive value(PPV)29.41%and 30.56%,and negative predictive value(NPV)93.75%and 97.78%,respectively.The cutoff HBsAg levels at 24 weeks predicting HBsAg loss at 96 weeks and 120 weeks of treatment were 174 IU/m L and 236 IU/mL respectively,with AUC 0.925 and 0.922,PPV 40.0%and 46.15%,and both NPV 100%.The predictive ability of the cutoff HBsAg levels at 24 weeks was better than that at 12 weeks for HBs Ag loss at either 96 or 120 weeks(χ~2=3.880,P=0.049 andχ~2=4.412,P=0.036).These results indicate that extended therapy is critical to HBsAg loss in HBe Ag-negative CHB patients during PEG-IFN treatment,and the HBsAg level at 24 weeks can be used to predict HBsAg loss during tailoring PEG-IFN therapy. | Minghui Li Lu Zhang Yao Lu Qiqi Chen Huihui Lu Fangfang Sun Zhan Zeng Gang Wan Linqing Zhao Yao Xie | 2021 | Virologica Sinica2021，36，2： | 15 |
| 13 | Organelle pH in the Arabidopsis Endomembrane System显示文摘细胞内部的分隔空间的 pH 为房间的生存能力是必要的。尽管有它的关联,很少对这些分隔空间的 pH 被知道。到在 vivo 的措施 pH,我们首先由联合修改溶解度的绿色的改进溶解度的特征产生了二个 pH 传感器荧光灯有 pHluorins 和 codon 的察觉到 pH 能力的蛋白质(GFP )(smGFP ) 在 Arabidopsis 为表示优化了。当 pH 与荧光消失在 pH 被降低, PEpHluorin (plant-solubility-modified 黄道 pHluorin ) 逐渐地失去荧光 6.2 并且 PRpHluorin (plant-solubility-modified ratiomatric pHluorin ) ,一个双刺激的传感器,允许精确大小。分隔空间特定的传感器被进一步熔化特定的排序的信号到 PEpHluorin 和 PRpHluorin 产生。我们的结果证明 cytosol 和原子核的 pH 是类似的(pH 7.3 和 7.2 ) 当 peroxisomes, mitochondrial 矩阵,和 plastidial 基质有碱的 pH 时。能分泌的小径的分隔空间揭示渐渐的使发酸,从 pH 跨越 7.1 在 endoplasmic 蜂窝胃(嗯) 到 pH 5.2 在液泡。令人惊讶地,在 trans-Golgi 网络(TGN ) 的 pH 和 multivesicular 身体(MVB ) 是,与 pH 6.3 和 6.2,相当类似。有 concanamycin A (ConcA ) 的 vacuolar 类型 H+-ATPase (V-ATPase ) 的抑制在 TGN 和液泡在 pH 引起了激烈的增加。总的来说, PEpHluorin 和 PRpHluorin 分别地是为在 vivo 的 pH 的可视化和 quantification 的优秀 pH 传感器。 | Jinbo Shen Yonglun Zeng Xiaohong Zhuang Lei Sun Xiaoqiang Yao Peter Pimpl Liwen Jiang | 2013 | Molecular Plant2013，6，5： | 14 |
| 14 | Hybrid graphene metasurfaces for highspeed mid-infrared light modulation and single-pixel imaging显示文摘During the past decades,major advances have been made in both the generation and detection of infrared light;however,its efficient wavefront manipulation and information processing still encounter great challenges.Efficient and fast optoelectronic modulators and spatial light modulators are required for mid-infrared imaging,sensing,security screening,communication and navigation,to name a few.However,their development remains elusive,and prevailing methods reported so far have suffered from drawbacks that significantly limit their practical applications.In this study,by leveraging graphene and metasurfaces,we demonstrate a high-performance free-space mid-infrared modulator operating at gigahertz speeds,low gate voltage and room temperature.We further pixelate the hybrid graphene metasurface to form a prototype spatial light modulator for high frame rate single-pixel imaging,suggesting orders of magnitude improvement over conventional liquid crystal or micromirror-based spatial light modulators.This work opens up the possibility of exploring wavefront engineering for infrared technologies for which fast temporal and spatial modulations are indispensable. | Beibei Zeng Zhiqin Huang Akhilesh Singh Yu Yao Abul K.Azad Aditya D.Mohite Antoinette J.Taylor David R.Smith Hou-Tong Chen | 2018 | Light(Science & Applications)2018，7，1： | 13 |
| 15 | Combination treatment with comprehensive cryoablation and immunotherapy in metastatic hepatocellular cancer显示文摘AIM: To retrospectively assess the effect of comprehensive cryosurgery (ablation of intraand extra-hepatic tumors) plus dendritic cell-cytokine-induced killer cell immunotherapy in metastatic hepatocellular cancer. METHODS: We divided 45 patients into cryo-immunotherapy (21 patients), cryotherapy (n = 12), immunotherapy (n = 5) and untreated (n = 7) groups. Overall survival (OS) after diagnosis of metastatic hepatocellular cancer was assessed after an 8-year follow-up. RESULTS: Median OS was higher following cryo-immu-notherapy (32 mo) or cryotherapy (17.5 mo; P < 0.05) than in the untreated group (3 mo) and was higher in the cryo-immunotherapy group than in the cryotherapy group (P < 0.05). In the cryo-immunotherapy group, median OS was higher after multiple treatments (36.5 mo) than after a single treatment (21 mo; P < 0.05). CONCLUSION: Cryotherapy and, especially, cryoimmunotherapy significantly increased OS in metastatic hepatocellular cancer patients. Multiple cryo-immunotherapy was associated with a better prognosis than single cryo-immunotherapy. | Li-Zhi Niu Jia-Liang Li Jian-Ying Zeng Feng Mu Meng-Tian Liao Fei Yao Li Li Chun-Yan Liu Ji-Bing Chen Jian-Sheng Zuo Ke-Cheng Xu | 2013 | World Journal of Gastroenterology2013，19，22： | 13 |
| 16 | Value of contrast-enhanced intraoperative ultrasound for cirrhotic patients with hepatocellular carcinoma:A report of 20 cases显示文摘AIM: To assess the clinical value of contrast-enhanced intraoperative ultrasound (CE-IOUS) as a novel tool in partial hepatectomy for cirrhotic patients with hepatocellular carcinoma (HCC). METHODS: From January 2007 to September 2007, a total of 20 consecutive cirrhotic patients with HCC scheduled to undergo partial hepatectomy were studied. Preoperative contrast enhanced computer tomography (CT) and/or magnetic resonance (MR) scans were performed within 1-2 wk before operation. Intraoperative ultrasound (IOUS) and CE-IOUS were carried out after mobilization of the liver. Lesions on precontrast and postcontrast scans were counted and mapped. CE-IOUS was performed with intravenous injection of ultrasound contrast agents SonoVue (Bracco Imaging, Milan, Italy). Arterial, portal and late phases of contrast enhancement were recorded and analyzed. Nodules showing arterial phase hyper-enhancing and/or hypo-enhancing in late parenchymal phase were considered malignant and removed surgically. Ultrasound-guided biopsy and ethanol ablation would be an option if the nodule could not be removed surgically. Newly detected nodules on IOUS showing iso-enhancement in both arterial and late phases were considered benign. These nodules were eitherremoved surgically if they were close to the main lesion or followed by examinations of alpha-fetoprotein (AFP) level and ultrasound and/or CT/MR every 3 mo. RESULTS: IOUS found 41 nodules in total, among which 17 (41.46%) were newly detected compared to preoperative imaging. Thirty-three nodules were diagnosed malignant by CE-IOUS, including one missed by IOUS. The sensitivity and specif icity of CE-IOUS on detecting HCC nodules are 100% (33/33 and 100% (9/9), respectively. Nine nodules were considered benign by CE-IOUS, four was confi rmed at histology and fi ve by follow-up. CE-IOUS changed the surgical strategy in 35% (7/20) of patients and avoid unnecessary intervention in 30% (6/20) of patients. CONCLUSION: CE-IOUS is a useful means to charac-terize the nodules detected by IOUS in cirrhotic liver, to fi nd isoechoic HCC nodules which can not be shown on IOUS and to improve the accuracy of conventional IOUS, thus it can be used as an essential tool in the surgical treatment of cirrhotic patients with HCC. | Qiang Lu Yan Luo Chao-Xin Yuan Yong Zeng Hong Wu Zheng Lei Yao Zhong Yu-Ting Fan Hong-Hao Wang Yang Luo | 2008 | World Journal of Gastroenterology2008，14，25： | 12 |
| 17 | Characteristics of the lunar samples returned by the Chang'E-5 mission显示文摘Forty-five years after the Apollo and Luna missions returned lunar samples,China's Chang’E-5(CE-5)mission collected new samples from the mid-latitude region in the northeastern Oceanus Procellarum of the Moon.Our study shows that 95%of CE-5 lunar soil sizes are found to be within the range of 1.40-9.35μm,while 95%of the soils by mass are within the size range of 4.84-432.27μm.The bulk density,true density and specific surface area of CE-5 soils are 1.2387 g/cm^(3),3.1952 g/cm^(3) and 0.56 m^(2)/g,respectively.Fragments from the CE-5 regolith are classified into igneous clasts(mostly basalt),agglutinate and glass.A few breccias were also found.The minerals and compositions of CE-5 soils are consistent with mare basalts and can be classified as low-Ti/low-Al/low-K type with lower rare-earth-element contents than materials rich in potassium,rare earth element and phosphorus.CE-5 soils have high FeO and low Mg index,which could represent a new class of basalt. | Chunlai Li Hao Hu Meng-Fei Yang Zhao-Yu Pei Qin Zhou Xin Ren Bin Liu Dawei Liu Xingguo Zeng Guangliang Zhang Hongbo Zhang Jianjun Liu Qiong Wang Xiangjin Deng Caijin Xiao Yonggang Yao Dingshuai Xue Wei Zuo Yan Su Weibin Wen Ziyuan Ouyang | 2022 | National Science Review2022，9，2： | 12 |
| 18 | Interaction of aerodynamic roughness length and windflow conditions and its parameterization over vegetation surface显示文摘Surface aerodynamic roughness length is usually taken as a constant. In fact, it displays a remarkable dynamic change over underlying vegetation surfaces, because of the coupling of land surface roughness elements and windflow conditions. Current international research on this dynamic change and associated mechanisms is very limited. Using observations from different underlying surfaces (including forest, farmland and grassland) provided by a northern China coordinated observation test, the variation of aerodynamic roughness length, along with wind speed and friction velocity, is analyzed. We introduce two relationship fits, between aerodynamic roughness length and wind speed u, and dynamic variable u2/u*. Results show that aerodynamic roughness length has a clear dynamic change, and has complicated interactions with near-surface windflow. Further, the relationship fits between aerodynamic roughness length, u and u2/u*, are not only related to the roughness properties of the underlying vegetation surface (e.g. plant height), but also to plant dynamic response characteristics (e.g. flexibility). Aerodynamic roughness length decreases with increasing wind speed, because near-surface windflow conditions can change both plant roughness properties and airflow. However, the change of aerodynamic roughness length with friction velocity is complicated, and its sensitivities and transition points significantly depend on vegetation type. For underlying surfaces of forest and corn, with relatively substantial vegetative cover, roughness length correlates well with wind speed. For a surface with short vegetative cover, like natural lawn, the correlation is low. However, for all of the three vegetative surfaces, there is a close relation between roughness length and u2/u*, and their coefficients of fit from testing essentially represent the plant height and flexibility of different vegetation types. The test results also indicate that the parameterized relationships of roughness length over the underlying vegetation surface hold prospects for application. | ZHANG Qiang ZENG Jian YAO Tong | 2012 | Chinese Science Bulletin2012，57，13： | 12 |
| 19 | Chloroquine enhances the cytotoxicity of topotecan by inhibiting autophagy in lung cancer cells显示文摘Although the anti-malaria drug chloroquine(CQ) has been shown to enhance chemotherapy and radiation sensitivity in clinical trials,the potential mechanisms underlying this enhancement are still unclear.Here,we examined the relevant mechanisms by which the multipotent CQ enhanced the cytotoxicity of topotecan(TPT).The lung cancer cell line A549 was treated with TPT alone or TPT combined with CQ at non-cytotoxic concentrations.Cell viability was assessed using the MTT assay.The percentage of apoptotic cells and the presence of a side population of cells were both determined by flow cytometry.Autophagy and the expression of Bcl-2 family proteins were examined by Western blotting.The accumulation of YFP-LC3 dots and the formation of acidic vesicular organelles were examined by confocal microscopy.CQ sensitized A549 cells to TPT and enhanced TPT-induced apoptosis in a Bcl-2 family protein-independent fashion.CQ inhibited TPT-induced autophagy,which modified the cytotoxicity of TPT.However,CQ failed to modify the transfer of TPT across the cytoplasmic membrane and did not increase lysosomal permeability.This study showed that CQ at non-cytotoxic concentrations potentiated the cytotoxicity of TPT by interfering with autophagy,implying that CQ has significant potential as a chemotherapeutic enhancer. | Yao Wang Rui-Qing Peng Dan-Dan Li Ya Ding Xiao-Qi Wu Yi-Xin Zeng Xiao-Feng Zhu Xiao-Shi Zhang | 2011 | Chinese Journal of Cancer2011，30，10： | 11 |
| 20 | A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B显示文摘BACKGROUND: Lamivudine was approved for the treat- ment of chronic hepatitis B in China in 1999; however the long-term result has not yet been reported in detail. This clinical trial was to evaluate the long-term efficacy and safe- ty of 3-year lamivudine treatment for chronic hepatitis B and the impact of emergence of YMDD mutation of hepa- titis B virus (HBV). METHODS: This multi-center, randomized, double-blind, placebo controlled trial began from 1996 to 1999. A total of 429 patients with serum HBsAg, HBeAg and HBV DNA positive were randomized to receive either lamivudine 100 mg daily (322 patients) or placebo (107) for the first 12 weeks. All patients were given subsequently open labelled lamivudine 100 mg/d for a total of 156 weeks. RESULTS: After 12-week lamivudine therapy, the levels of serum HBV DNA decreased rapidly. The negativity of HBV DNA (<1.6 pg/ml) at week 12 was 92.2% in the lamivudine group, whereas it was only 14.1% in the place- bo group (P<0.01). After 1-year lamivudine treatment, 72.7% of the patients showed undetectable serum HBV DNA (<1.6 pg/ml). At the end of 3 years, serum HBV DNA continued to be substantially suppressed with a me- dian level below a detectable level in patients with non-YM- DD variant HBV, which was increased to 86 mEq/ml (bD- NA method, equivalent hybridization method 10 pg/ml) in patients with YMDD mutation. At the end of 1, 2 and 3 years, the rates of HBeAg loss were 9.5%, 16.8% and 20.0% respectively and the rates of HBeAg/anti-HBe sero- conversion were 8.3%, 11.5% and 17.3%. The rates of HBeAg loss and seroconversion were correlated with the baseline level of ALT. In patients with a baseline level of alanine transaminase (ALT)>2 × upper limit of normal (ULN) and ALT >5×ULN, the rates of HBeAg loss were 42.2% and 66.7%, and the rates of seroconversion were34.4% and 61.1% respectively (P<0.01) at the end of year 3. The levels of ALT at year 3 remained normal in 58.8% of patients whose baseline level of ALT was elevated, and in 79.1% of patients whose level of ALT was normal before treatment. YMDD mutations occurred in 12.1%, 49.7% and 70.5% of patients respectively at year 1, 2 and 3. In pa- tients with YMDD mutation, the levels of HBV DNA were increased slightly with mild to moderate elevation of ALT level. HBeAg loss and seroconversion were 20.0% and 15.1% in patients with YMDD mutation at the end of year 3, which were lower than those in non-variant patients (P<0.01). Adverse drug reactions or events varied gene- rally from mild to moderate. In 2 patients serious adverse events (fatigue and abdominal distension) were related to medication. ALT flares (ALT>5×ULN) occurred in 17 patients: 10 were YMDD mutants and 7 were non-mutants; all of them were relieved. No death occurred in the period of 3 years. CONCLUSION: Sustained inhibition of HBV replication and clinical improvement could be obtained after 3-year lamivudine therapy of good tolerance and safety. | Guang-Bi Yao, Zhen-Yu Cui, Bao-En Wang, Ji-Lu Yao and Min-De Zeng Shanghai, China Shanghai Jing-An Qu Central Hospital, Shanghai 200040, China Beijing Ditan Hospital, Beijing 100011 , China Beijing Friendship Hospital, Beijing 100050, China 3rd Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510630, Chinaand Shanghai Renji Hospital, Shanghai Second Medical University, Shanghai 200001 , China | 2004 | Hepatobiliary & Pancreatic Diseases International2004，3，2： | 11 |
您所在的机构暂未开通此部分的功能，请联系管理员